Godavari Drugs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 11, 2025, 3:36 am

Competitors of Godavari Drugs Ltd

All Competitor Stocks of Godavari Drugs Ltd

Quarterly Result

Last Updated: August 19, 2025, 2:35 pm

Below is a detailed analysis of the quarterly data for Godavari Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 23.81 Cr.. The value appears to be declining and may need further review. It has decreased from 25.50 Cr. (Mar 2025) to 23.81 Cr., marking a decrease of 1.69 Cr..
• For Expenses, as of Jun 2025, the value is 20.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.39 Cr. (Mar 2025) to 20.91 Cr., marking a decrease of 1.48 Cr..
• For Operating Profit, as of Jun 2025, the value is 2.90 Cr.. The value appears to be declining and may need further review. It has decreased from 3.11 Cr. (Mar 2025) to 2.90 Cr., marking a decrease of 0.21 Cr..
• For OPM %, as of Jun 2025, the value is 12.18%. The value appears to be declining and may need further review. It has decreased from 12.20% (Mar 2025) to 12.18%, marking a decrease of 0.02%.
• For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.10 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.11 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 0.11 Cr..
• For Depreciation, as of Jun 2025, the value is 0.60 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.67 Cr. (Mar 2025) to 0.60 Cr., marking a decrease of 0.07 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.31 Cr.. The value appears to be declining and may need further review. It has decreased from 1.44 Cr. (Mar 2025) to 1.31 Cr., marking a decrease of 0.13 Cr..
• For Tax %, as of Jun 2025, the value is 19.85%. The value appears to be improving (decreasing) as expected. It has decreased from 38.19% (Mar 2025) to 19.85%, marking a decrease of 18.34%.
• For Net Profit, as of Jun 2025, the value is 1.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.89 Cr. (Mar 2025) to 1.04 Cr., marking an increase of 0.15 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.38. The value appears strong and on an upward trend. It has increased from 1.18 (Mar 2025) to 1.38, marking an increase of 0.20.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 1:02 pm

Growth

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:58 am

Below is a detailed analysis of the balance sheet data for Godavari Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
• For Reserves, as of Sep 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 2.00 Cr..
• For Borrowings, as of Sep 2025, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 64.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 10.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 8.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 143.00 Cr. (Mar 2025) to 162.00 Cr., marking an increase of 19.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
• For CWIP, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 11.00 Cr..
• For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Other Assets, as of Sep 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 90.00 Cr., marking an increase of 9.00 Cr..
• For Total Assets, as of Sep 2025, the value is 162.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 162.00 Cr., marking an increase of 19.00 Cr..

However, the Borrowings (74.00 Cr.) are higher than the Reserves (38.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Godavari Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
• For Diluted EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
• For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. It has decreased from 10.02 (Mar 24) to 9.07, marking a decrease of 0.95.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.56. It has increased from 51.74 (Mar 24) to 57.56, marking an increase of 5.82.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.56. It has increased from 51.74 (Mar 24) to 57.56, marking an increase of 5.82.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 150.52. It has decreased from 208.10 (Mar 24) to 150.52, marking a decrease of 57.58.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 17.00. This value is within the healthy range. It has decreased from 18.49 (Mar 24) to 17.00, marking a decrease of 1.49.
• For PBIT / Share (Rs.), as of Mar 25, the value is 13.75. This value is within the healthy range. It has decreased from 15.84 (Mar 24) to 13.75, marking a decrease of 2.09.
• For PBT / Share (Rs.), as of Mar 25, the value is 7.47. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 7.47, marking a decrease of 1.72.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
• For PBDIT Margin (%), as of Mar 25, the value is 11.29. This value is within the healthy range. It has increased from 8.88 (Mar 24) to 11.29, marking an increase of 2.41.
• For PBIT Margin (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 7.61 (Mar 24) to 9.13, marking an increase of 1.52.
• For PBT Margin (%), as of Mar 25, the value is 4.96. This value is below the healthy minimum of 10. It has increased from 4.41 (Mar 24) to 4.96, marking an increase of 0.55.
• For Net Profit Margin (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has increased from 3.54 (Mar 24) to 3.86, marking an increase of 0.32.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.10. This value is below the healthy minimum of 15. It has decreased from 14.24 (Mar 24) to 10.10, marking a decrease of 4.14.
• For Return on Capital Employeed (%), as of Mar 25, the value is 14.79. This value is within the healthy range. It has decreased from 22.60 (Mar 24) to 14.79, marking a decrease of 7.81.
• For Return On Assets (%), as of Mar 25, the value is 3.06. This value is below the healthy minimum of 5. It has decreased from 4.11 (Mar 24) to 3.06, marking a decrease of 1.05.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.28 (Mar 24) to 0.55, marking an increase of 0.27.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.42. This value exceeds the healthy maximum of 1. It has decreased from 1.43 (Mar 24) to 1.42, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has decreased from 1.22 (Mar 24) to 0.81, marking a decrease of 0.41.
• For Current Ratio (X), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 1.08.
• For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.82 (Mar 24) to 0.69, marking a decrease of 0.13.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.67. This value is within the healthy range. It has decreased from 6.02 (Mar 24) to 4.67, marking a decrease of 1.35.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.71. This value is below the healthy minimum of 3. It has decreased from 2.83 (Mar 24) to 2.71, marking a decrease of 0.12.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.15 (Mar 24) to 1.93, marking a decrease of 0.22.
• For Enterprise Value (Cr.), as of Mar 25, the value is 125.12. It has increased from 123.00 (Mar 24) to 125.12, marking an increase of 2.12.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 1.10, marking an increase of 0.32.
• For EV / EBITDA (X), as of Mar 25, the value is 9.77. This value is within the healthy range. It has increased from 8.83 (Mar 24) to 9.77, marking an increase of 0.94.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 24) to 0.58, marking an increase of 0.14.
• For Price / BV (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.52, marking a decrease of 0.28.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 24) to 0.58, marking an increase of 0.14.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness